+852 3460 3857

體外反搏治療改善輕至中度心臟衰竭患者的運動耐受力、生活質量和紐約心臟協會功能分級

EECP Improved Exercise Tolerance, Quality Of Life, and NYHA Functional Classification

Source From 資料來源 : https://www.sciencedirect.com/science/article/pii/S0735109706011296?via%3Dihub

 

EECP Improved Exercise Tolerance, Quality Of Life, and NYHA Functional Classification

OBJECTIVES:

The PEECH (Prospective Evaluation of Enhanced External Counterpulsation in Congestive Heart Failure) study assessed the benefits of enhanced external counterpulsation (EECP) in the treatment of patients with mild-to-moderate heart failure (HF).

BACKGROUND:

Enhanced external counterpulsation reduced angina symptoms and extended time to exercise-induced ischemia in patients with coronary artery disease, angina, and normal left ventricular function. A small pilot study and registry analysis suggested benefits in patients with HF.

METHODS:

We randomized 187 subjects with mild-to-moderate symptoms of HF to either EECP and protocol-defined pharmacologic therapy (PT) or PT alone. Two co-primary end points were pre-defined: the percentage of subjects with a 60 s or more increase in exercise duration and the percentage of subjects with at least 1.25 ml/min/kg increase in peak volume of oxygen uptake (VO2) at 6 months.

RESULTS:

By the primary intent-to-treat analysis, 35% of subjects in the EECP group and 25% of control subjects increased exercise time by at least 60 s (p = 0.016) at 6 months. However, there was no between-group difference in peak VO2 changes. New York Heart Association (NYHA) functional class improved in the active treatment group at 1 week (p < 0.01), 3months (p < 0.02), and 6 months (p < 0.01). The Minnesota Living with Heart Failure score improved significantly 1 week (p < 0.02) and 3 months after treatment (p = 0.01).

CONCLUSIONS:

In this randomized, single-blinded study, EECP improved exercise tolerance, quality of life, and NYHA functional classification without an accompanying increase in peak VO2.

 

增強體外反搏可提高慢性心力衰竭患者的運動耐量

目標

PEECH(慢性心臟衰竭中體外反搏的前瞻性評估)研究評估了體外反搏治療(EECP)在輕至中度心臟衰竭(HF)患者治療中的益處。

背景

體外反搏可減少冠狀動脈疾病、心絞痛和正常左心室功能患者的心絞痛症狀,並延長運動誘導缺血時間。一項小型試驗和註冊分析表明對HF患者也有益處。

方法

我們將187名輕至中度HF症狀的受試者隨機分配到接受EECP和符合協議的藥物治療(PT)或僅接受PT的組別。預先定義了兩個共同主要終點:運動持續時間增加60秒或更多的受試者的百分比,以及6個月內峰值氧氣攝取量(VO2)增加至少1.25 ml/min/kg的受試者的百分比。

結果

根據主要意圖分析,EECP組中有35%的受試者和對照組中有25%的受試者在6個月內運動時間增加了至少60秒。然而,在峰值VO2變化方面,兩組之間沒有差異。主動治療組在1週、3個月和6個月時的紐約心臟協會(NYHA)功能分級有所改善。心臟衰竭患者的明尼蘇達心臟衰竭生活評分在治療後1週和3個月明顯改善。

結論:在這項隨機、單盲研究中,EECP改善了 運動耐受力 、生活質量和NYHA功能分級,而峰值VO2則沒有相應增加。

WhatsApp chat